Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187382
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gimenez Arnau, A. | - |
dc.contributor.author | Bartra Tomàs, Joan | - |
dc.contributor.author | Ferrer, M. | - |
dc.contributor.author | Jauregui, I. | - |
dc.contributor.author | Borbujo, J. | - |
dc.contributor.author | Figueras Nart, Ignasi | - |
dc.contributor.author | Muñoz Bellido, F. J. | - |
dc.contributor.author | Pedraz Muñoz, Javier | - |
dc.contributor.author | Serra Baldrich, Esther | - |
dc.contributor.author | Tejedor Alonso, Miguel Ángel | - |
dc.contributor.author | Velasco, M. | - |
dc.contributor.author | Terradas, P. | - |
dc.contributor.author | Labrador, M. | - |
dc.date.accessioned | 2022-07-06T07:45:38Z | - |
dc.date.available | 2022-07-06T07:45:38Z | - |
dc.date.issued | 2020-12-21 | - |
dc.identifier.issn | 1018-9068 | - |
dc.identifier.uri | http://hdl.handle.net/2445/187382 | - |
dc.description.abstract | Objective: During its first year, the AWARE study assessed disease activity, patient quality of life (QOL), and treatment patterns in chronic urticaria (CU) refractory to H1-antihistamines (H1-AH) in clinical practice. Methods: We performed an observational, prospective (24 months), international, multicenter study. The inclusion criteria were age _>18 years and H1-AH-refractory CU (>2 months). At each visit, patients completed questionnaires to assess disease burden (Urticaria Control Test [UCT]), disease activity (7 day-Urticaria Activity Score [UAS7]), and QOL (Dermatology Life Quality index [DLQI], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL], and Angioedema Quality of Life Questionnaire [AE-QoL]). We present data for Spain. Results: The study population comprised 270 evaluable patients (73.3% female, mean [SD] age, 48.9 [14.7] years). At baseline, 89.3% were prescribed a CU treatment. After 1 year, first-and second-line treatments became less frequent and third-line treatments became more frequent. At baseline, 47.0% of patients experienced angioedema; at 1 year, this percentage had fallen to 11.8%. The mean (SD) AE-QoL score decreased from 45.2 (28.7) to 24.0 (25.8). The mean (SD) UCT score decreased from 7.0 (4.5) to 12.1 (4.1). According to UAS7, 38.2% of patients reported absence of wheals and itch in the previous 7 days at 1 year compared with 8.3% at baseline. The mean (SD) DLQI score decreased from 8.0 (7.4) to 2.8 (4.6). At the 1-year visit, the percentage of patients reporting a high or very high impact on QOL fell from 29.9% to 9.6%. Conclusions: H1-AH-refractory CU in Spain is characterized by absence of symptoms and a considerable impact on QOL. Continuous follow-up of CU patients and third-line therapies reduce disease burden and improve patients' QOL. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Esmon | - |
dc.relation.isformatof | Postprint del document publicat a: https://doi.org/10.18176/jiaci.0661 | - |
dc.relation.ispartof | Journal of Investigational Allergology and Clinical Immunology, 2020, vol. 32, num. 3, p. 191-199 | - |
dc.relation.uri | https://doi.org/10.18176/jiaci.0661 | - |
dc.rights | (c) Esmon, 2022 | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Urticària | - |
dc.subject.classification | Qualitat de vida | - |
dc.subject.other | Urticaria | - |
dc.subject.other | Quality of life | - |
dc.title | A Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2022-07-04T12:05:05Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33349612 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
vol32issue3_3.pdf | 441.46 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.